OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue ...
Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical need Springboard ...
PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback